Back

Presentation of ONCOS-102 melanoma data at SITC Annual Meeting

Oslo, Norway, 11 November 2019 – Targovax ASA (OSE: TRVX), announces that clinical data from its combination trial with ONCOS-102 and Keytruda in anti-PD1 refractory melanoma was presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Dr. Shoushtari, MD, Medical Oncologist, Memorial Sloan Kettering, presented results from part 1 of Targovax’s phase I trial in anti-PD1 refractory melanoma combining ONCOS-102 with Keytruda. Headline data were released in July, showing that three out of nine patients had significant reduction of tumor burden (33% overall response rate, ORR), including one patient with a complete response, which is rarely seen in this late-stage patient population Please see the full presentation here: SITC presentation

Øystein Soug, CEO of Targovax, commented: “Although the number of patients is small, 33% ORR is very encouraging and confirms our hypothesis that ONCOS-102 can immune activate PD-1 refractory tumors to respond to re-challenge with Keytruda. We are very excited that these data are being recognized with an oral presentation at the SITC Annual Meeting.”

Part 2 of the trial is currently enrolling patients, where an extended ONCOS-102 dosing regimen is being assessed.

An extended presentation will be given by Dr. Shoushtari at an investor event in NYC later this week:

SOLEBURY TROUT KOL DAY

Date: 15 November 2019
Time and place 2 pm ET; NYC, US
Presenter: Dr. Alexander Shoushtari, Principal Investigator, Memorial Sloan Kettering Cancer Center, NYC
Webcast: https://services.choruscall.com/links/trvx191115.html
For more information about the Solebury Trout KOL day or to RSVP, institutional investors and sell-side analysts may contact .

KOL biography:
Alexander N. Shoushtari, MD, Medical Oncologist, Memorial Sloan Kettering

Dr. Shoushtari is a renowned expert in melanoma, with a research focus on uveal and mucosal melanomas. He has been part of several immunotherapy trials at MSKCC and is the Principal Investigator on the ONCOS-102 phase I trial in CPI refractory advanced melanoma. Dr. Shoushtari is a member of the research team of Dr. Jedd Wolchok, MD, PhD, Chief, Melanoma and Immunotherapeutics Service at the Memorial Sloan Kettering Cancer Center.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: 

Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: 

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer.

ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has already shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.